Compare Coursera Inc (COUR) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs TransMedics Group Inc — how do they compare? Coursera Inc trades at $5.65 (market cap $1.50B), while TransMedics Group Inc trades at $87.11 (market cap $3.10B). The key difference: TransMedics Group Inc is far larger — about 2.1× Coursera Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| COUR | TMDX | |
|---|---|---|
Market Cap | $1.50B | $3.10B |
Sector | Consumer Staples | Technology |
52-Week High | $12.20 | $150.42 |
52-Week Low | $5.09 | $61.99 |
Enterprise Value | $759.54M | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.575, down 3.21% today, with a bearish technical signal and mixed earnings performance. Revenue growth continues with 2025 reaching $757.5M, though the company remains unprofitable with a -15.39% net margin. Recent Q2 2026 earnings beat expectations at $0.17 per share versus $0.10 expected. Analyst sentiment is positive with 53% buy ratings and a $7.70 consensus price target representing 38% upside potential.
The stock offers growth exposure to online education but faces profitability challenges. Upside catalysts include continued revenue expansion and strategic AI investments, while risks include persistent losses and competitive pressures. Wall Street sees significant undervaluation despite near-term headwinds.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
